2024. Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON trials. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s492. DOI:https://doi.org/10.25251/skin.8.supp.492.